JP2008519042A - インフルエンザワクチン接種 - Google Patents

インフルエンザワクチン接種 Download PDF

Info

Publication number
JP2008519042A
JP2008519042A JP2007540074A JP2007540074A JP2008519042A JP 2008519042 A JP2008519042 A JP 2008519042A JP 2007540074 A JP2007540074 A JP 2007540074A JP 2007540074 A JP2007540074 A JP 2007540074A JP 2008519042 A JP2008519042 A JP 2008519042A
Authority
JP
Japan
Prior art keywords
influenza virus
patient
immunogenic composition
influenza
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007540074A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008519042A5 (https=
Inventor
デレク オヘーガン，
Original Assignee
ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36578359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2008519042(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド filed Critical ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド
Publication of JP2008519042A publication Critical patent/JP2008519042A/ja
Publication of JP2008519042A5 publication Critical patent/JP2008519042A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0046—Solid microneedles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0061—Methods for using microneedles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2007540074A 2004-11-03 2005-11-03 インフルエンザワクチン接種 Pending JP2008519042A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62497304P 2004-11-03 2004-11-03
PCT/US2005/039982 WO2006062637A2 (en) 2004-11-03 2005-11-03 Influenza vaccination

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011219630A Division JP2012001565A (ja) 2004-11-03 2011-10-03 インフルエンザワクチン接種

Publications (2)

Publication Number Publication Date
JP2008519042A true JP2008519042A (ja) 2008-06-05
JP2008519042A5 JP2008519042A5 (https=) 2011-11-24

Family

ID=36578359

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007540074A Pending JP2008519042A (ja) 2004-11-03 2005-11-03 インフルエンザワクチン接種
JP2011219630A Pending JP2012001565A (ja) 2004-11-03 2011-10-03 インフルエンザワクチン接種
JP2014081555A Pending JP2014132035A (ja) 2004-11-03 2014-04-11 インフルエンザワクチン接種

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011219630A Pending JP2012001565A (ja) 2004-11-03 2011-10-03 インフルエンザワクチン接種
JP2014081555A Pending JP2014132035A (ja) 2004-11-03 2014-04-11 インフルエンザワクチン接種

Country Status (9)

Country Link
US (2) US20090004222A1 (https=)
EP (2) EP2923711A1 (https=)
JP (3) JP2008519042A (https=)
CN (1) CN101076355A (https=)
AU (1) AU2005314563B2 (https=)
CA (1) CA2586690A1 (https=)
ES (1) ES2542020T3 (https=)
HK (1) HK1214534A1 (https=)
WO (1) WO2006062637A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010013601A1 (ja) * 2008-07-30 2010-02-04 久光製薬株式会社 マイクロニードルデバイスおよびマイクロニードルデバイスによる日本脳炎ウイルス抗原の奏功性を上昇させる方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
EP2441471B1 (en) 2005-03-08 2014-10-08 MedImmune, LLC Reassortant influenza viruses
WO2010006144A2 (en) * 2008-07-11 2010-01-14 Medlmmune, Llc. Influenza hemagglutinin and neuraminidase variants
IN2014CN02114A (https=) * 2011-09-20 2015-05-29 Sinai School Medicine
JP6411378B2 (ja) * 2013-02-01 2018-10-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｔｏｌｌ様受容体アゴニストを含む免疫学的組成物の皮内送達
MX2020004151A (es) 2017-10-30 2020-08-13 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.
EP3740241A1 (en) * 2018-01-18 2020-11-25 eTheRNA Immunotherapies NV Lipid nanoparticles
EP3959216A4 (en) 2019-04-24 2023-01-11 Icahn School of Medicine at Mount Sinai ANTI-INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF
BR112022022039A2 (pt) 2020-04-28 2022-12-13 Ticona Llc Conjunto de microagulhas

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000507448A (ja) * 1996-04-01 2000-06-20 カイロン ベーリング ゲーエムベーハー アンド カンパニー インフルエンザウイルスの複製のための動物細胞および方法
WO2003076601A1 (fr) * 2002-03-08 2003-09-18 Vivalis Lignées de cellules aviaires utiles pour la production de substances d'intérêt
JP2004531578A (ja) * 2001-06-29 2004-10-14 ベクトン・ディキンソン・アンド・カンパニー ワクチンおよび遺伝子治療剤のマイクロカニューレによる皮内送達
JP2004532830A (ja) * 2001-02-23 2004-10-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規なワクチン
WO2005099751A2 (en) * 2004-04-01 2005-10-27 Alza Corporation Apparatus and method for transdermal delivery of influenza vaccine

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1122527A (en) 1979-05-15 1982-04-27 Karen K. Brown Influenza vaccine production in liquid cell culture
HU212924B (en) * 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
CA2054228A1 (en) 1990-10-30 1992-05-01 Masaharu Oki Muramyldipeptide derivatives and influenza vaccine comprising the derivatives
WO1994019013A1 (en) 1993-02-19 1994-09-01 Smithkline Beecham Corporation Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
ATE157882T1 (de) * 1993-03-23 1997-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
GB9500788D0 (en) 1995-01-16 1995-03-08 Medeva Holdings Bv Vaccine compositions
EP0865296B1 (en) 1995-10-20 2002-02-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Influenza vaccine
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
US6503231B1 (en) 1998-06-10 2003-01-07 Georgia Tech Research Corporation Microneedle device for transport of molecules across tissue
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
US6611707B1 (en) 1999-06-04 2003-08-26 Georgia Tech Research Corporation Microneedle drug delivery device
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US6843781B2 (en) * 1999-10-14 2005-01-18 Becton, Dickinson And Company Intradermal needle
GB0017999D0 (en) 2000-07-21 2000-09-13 Smithkline Beecham Biolog Novel device
JP2004536785A (ja) * 2001-02-23 2004-12-09 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規なワクチン
US20020193729A1 (en) 2001-04-20 2002-12-19 Cormier Michel J.N. Microprojection array immunization patch and method
TWI228420B (en) * 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US20050123550A1 (en) 2003-05-12 2005-06-09 Laurent Philippe E. Molecules enhancing dermal delivery of influenza vaccines
US7588774B2 (en) * 2003-05-12 2009-09-15 Becton, Dickinson And Company Molecules enhancing dermal delivery of influenza vaccines
CA2690196A1 (en) * 2007-06-18 2008-12-24 Medimmune, Llc Influenza b viruses having alterations in the hemaglutinin polypeptide

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000507448A (ja) * 1996-04-01 2000-06-20 カイロン ベーリング ゲーエムベーハー アンド カンパニー インフルエンザウイルスの複製のための動物細胞および方法
JP2004532830A (ja) * 2001-02-23 2004-10-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規なワクチン
JP2004531578A (ja) * 2001-06-29 2004-10-14 ベクトン・ディキンソン・アンド・カンパニー ワクチンおよび遺伝子治療剤のマイクロカニューレによる皮内送達
WO2003076601A1 (fr) * 2002-03-08 2003-09-18 Vivalis Lignées de cellules aviaires utiles pour la production de substances d'intérêt
WO2005099751A2 (en) * 2004-04-01 2005-10-27 Alza Corporation Apparatus and method for transdermal delivery of influenza vaccine

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN6012003542; ＭＡＴＲＩＡＮＯ，Ｊ．Ａ．　ｅｔ　ａｌ: 'Ｍａｃｒｏｆｌｕｘ　ｍｉｃｒｏｐｒｏｊｅｃｔｉｏｎ　ａｒｒａｙ　ｐａｔｃｈ　ｔｅｃｈｎｏｌｏｇｙ：　ａ　ｎｅｗ　ａｎｄ　ｅｆｆｉｃｉｅｎｔ　ａｐｐｒｏａｃｈ　ｆｏｒ　ｉｎｔｒａｃｕｔａｎｅｏｕｓ　ｉｍ' Ｐｈａｒｍ　Ｒｅｓ Ｖｏｌ．１９，　Ｎｏ．１, 2002, ｐ．６３-７０ *
JPN6012003545; 'Ｍａｃｒｏｆｌｕｘ　ｔｒａｎｓｄｅｒｍａｌ　ｔｅｃｈｎｏｌｏｇｙ　ｄｅｖｅｌｏｐｍｅｎｔ　ｆｏｒ　ｔｈｅ　ｄｅｌｉｖｅｒｙ　ｏｆ　ｔｈｅｒａｐｅｕｔｉｃ　ｐｅｐｔｉｄｅｓ　ａｎｄ　ｐｒｏｔｅｉｎｓ' Ｄｒｕｇ　Ｄｅｌｉｖｅｒｙ　Ｔｅｃｈｎｏｌｏｇｙ Ｖｏｌ．２，　Ｎｏ．５, 2002 *
JPN6012003547; ＣＯＲＭＩＥＲ，Ｍ．　ｅｔ　ａｌ: 'Ｔｒａｎｓｄｅｒｍａｌ　ｄｅｌｉｖｅｒｙ　ｏｆ　ｄｅｓｍｏｐｒｅｓｓｉｎ　ｕｓｉｎｇ　ａ　ｃｏａｔｅｄ　ｍｉｃｒｏｎｅｅｄｌｅ　ａｒｒａｙ　ｐａｔｃｈ　ｓｙｓｔｅｍ' Ｊｏｕｒｎａｌ　ｏｆ　ｃｏｎｔｒｏｌｌｅｄ　ｒｅｌｅａｓｅ　：　ｏｆｆｉｃｉａｌ　ｊｏｕｒｎａｌ　ｏｆ　ｔｈｅ　Ｃｏｎｔｒｏｌｌｅｄ　Ｒｅｌｅａｓｅ　Ｓｏｃｉｅｔｙ Ｖｏｌ．９７，　Ｎｏ．３, 200407, ｐ．５０３-１１ *
JPN6012003549; ＣＯＲＭＩＥＲ，Ｍ．　ｅｔ　ａｌ: 'Ｍａｃｒｏｆｌｕｘ　ｔｅｃｈｎｏｌｏｇｙ　ｆｏｒ　ｔｒａｎｓｄｅｒｍａｌ　ｄｅｌｉｖｅｒｙ　ｏｆ　ｔｈｅｒａｐｅｕｔｉｃ　ｐｒｏｔｅｉｎｓ　ａｎｄ　ｖａｃｃｉｎｅｓ' Ｄｒｕｇｓ　ａｎｄ　ｔｈｅ　Ｐｈａｒｍａｃｅｕｔｉｃａｌ　Ｓｃｉｅｎｃｅｓ Ｖｏｌ．１２６, 2003, ｐ．５８９-５９８ *
JPN6012003550; ＢＲＵＨＬ，Ｐ．　ｅｔ　ａｌ: 'Ｈｕｍｏｒａｌ　ａｎｄ　ｃｅｌｌ-ｍｅｄｉａｔｅｄ　ｉｍｍｕｎｉｔｙ　ｔｏ　ｖｅｒｏ　ｃｅｌｌ-ｄｅｒｉｖｅｄ　ｉｎｆｌｕｅｎｚａ　ｖａｃｃｉｎｅ' Ｖａｃｃｉｎｅ Ｖｏｌ．１９，　Ｎｏ．９-１０, 2000, ｐ．１１４９-５８ *
JPN6012003551; ＰＡＵ，Ｍ．Ｇ．　ｅｔ　ａｌ: 'Ｔｈｅ　ｈｕｍａｎ　ｃｅｌｌ　ｌｉｎｅ　ＰＥＲ．Ｃ６　ｐｒｏｖｉｄｅｓ　ａ　ｎｅｗ　ｍａｎｕｆａｃｔｕｒｉｎｇ　ｓｙｓｔｅｍ　ｆｏｒ　ｔｈｅ　ｐｒｏｄｕｃｔｉｏｎ　ｏｆ　ｉｎｆｌｕｅｎｚａ　ｖａｃｃｉ' Ｖａｃｃｉｎｅ Ｖｏｌ．１９，　Ｎｏ．１７-１９, 2001, ｐ．２７１６-２１ *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010013601A1 (ja) * 2008-07-30 2010-02-04 久光製薬株式会社 マイクロニードルデバイスおよびマイクロニードルデバイスによる日本脳炎ウイルス抗原の奏功性を上昇させる方法
JP5744517B2 (ja) * 2008-07-30 2015-07-08 久光製薬株式会社 マイクロニードルデバイスおよびマイクロニードルデバイスによる日本脳炎ウイルス抗原の奏功性を上昇させる方法
KR101622738B1 (ko) 2008-07-30 2016-05-19 히사미쓰 세이야꾸 가부시키가이샤 마이크로니들 디바이스 및 마이크로니들 디바이스에 의한 일본 뇌염 바이러스 항원의 주효성을 상승시키는 방법

Also Published As

Publication number Publication date
WO2006062637A2 (en) 2006-06-15
AU2005314563B2 (en) 2011-06-30
JP2014132035A (ja) 2014-07-17
JP2012001565A (ja) 2012-01-05
EP1807116A4 (en) 2007-10-31
EP1807116B1 (en) 2015-05-06
US20150299269A1 (en) 2015-10-22
ES2542020T3 (es) 2015-07-29
CA2586690A1 (en) 2006-06-15
EP2923711A1 (en) 2015-09-30
EP1807116A2 (en) 2007-07-18
CN101076355A (zh) 2007-11-21
WO2006062637A3 (en) 2006-08-17
US20090004222A1 (en) 2009-01-01
HK1214534A1 (en) 2016-07-29
US10112979B2 (en) 2018-10-30
AU2005314563A1 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
JP2014132035A (ja) インフルエンザワクチン接種
Vassilieva et al. Improved immunogenicity of individual influenza vaccine components delivered with a novel dissolving microneedle patch stable at room temperature
Quan et al. Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles
JP5712126B2 (ja) 遅延型追加刺激免疫処置に対する迅速な応答
Skountzou et al. Skin immunization with influenza vaccines
WO2017122635A1 (ja) 固定化ウイルス粒子を含むワクチン
TWI801328B (zh) 包括咪喹莫特的局部調配物之用途
JP2008519042A5 (https=)
CN101450209B (zh) 透皮免疫流感多价疫苗的制备及其方法
CN114761040A (zh) 用于增强对疫苗接种的免疫反应和改善疫苗生产的组合物和方法
JP2002529427A (ja) 薬学的作用物質の調合物および投与器具
Glück Intranasal immunization against influenza
CN101754770B (zh) 皮内流感疫苗
Delem et al. Comparison of the protective efficacies of the live vaccine RIT 4025 and an inactivated vaccine against a natural heterologous A/Victoria/3/75 infection
Xu et al. Journal of Vaccines & Immunization Volume 4, Issue 1, August 2016, Pages 1–8 Original research Open Access
Xu Journal of Vaccines & Immunization
Carey A new look at influenza vaccination

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080813

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110829

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110905

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20111003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120416

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120725

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121012